Abstract 1755P
Background
Obesity is a strong risk factor for cancer, with more than 40,000 diagnosed cancers every year attributed to obesity. The role of nutrition in obesity-related cancers (ORC) needs to be better understood to develop tailored prevention strategies. The quality, rather than the quantity, of carbohydrate intake, seems to play a significant role. We investigated the relationship between dietary carbohydrate quality and risk of developing ORC in the "Seguimiento Universidad de Navarra” (SUN) Mediterranean cohort.
Methods
A total of 18,446 Spanish university graduates [mean age 38 years (SD 12), 61% women, mean BMI 23.5 kg/m2 (SD 3.5 kg/m2)], with no personal history of cancer, were followed-up for a median of 13.7 years. Baseline carbohydrate quality index (CQI) was assessed using 4 previously defined criteria: high dietary fibre intake, low glycemic index, high whole-grain: total-grain ratio and high solid carbohydrate: total carbohydrate ratio. Subjects were classified into tertiles according to their CQI score. Obesity-related incident cases were confirmed by an oncologist using medical records and by querying the National Death Index blindly to dietary exposures.
Results
During follow-up, 269 incident cases of obesity-related cancer were confirmed. A higher quality of carbohydrate intake, as measured by the baseline CQI, was associated with a lower risk of ORC with multivariable-adjusted hazard ratio (HR) for the upper (T3) versus the lowest tertile (T1) of 0.68 (95% confidence interval: 0.48, 0.97). Particularly, a higher dietary fibre intake was inversely associated with ORC, HR T3 vs. T1 = 0.58 (0.38, 0.89).
Conclusions
In this Mediterranean cohort, we observed a significant inverse association between a better global quality of carbohydrate intake and the risk of obesity-related cancers. This finding suggests that strategies for cancer prevention should emphasize the quality of carbohydrate intake, and particularly the dietary fibre intake.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Navarra.
Funding
Spanish Government-Instituto de Salud Carlos III, and the European Regional Development Fund (FEDER) (RD 06/0045, CIBER-OBN, Grants PI10/02658, PI10/02293, PI13/00615, PI14/01668, PI14/01798, PI14/01764, PI17/01795, PI20/00564 and G03/140), the Navarra Regional Government (27/2011, 45/2011, 122/2014), and the University of Navarra.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1902P - Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO+IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)
Presenter: Audreylie Lemelin
Session: Poster session 23
1903P - Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
Presenter: Viktor Gruenwald
Session: Poster session 23
1904P - Treatment options and outcome of metastatic renal cell carcinoma patients with brain or bone metastases: A real-world evidence from a German retrospective multi-center analysis
Presenter: Pia Paffenholz
Session: Poster session 23
1905P - Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster session 23
1906P - Metastasized non-clear cell renal cell carcinoma: Which entities are dangerous? Results learned from reference pathology of the SuniForecast study
Presenter: Arndt Hartmann
Session: Poster session 23
1907P - Multi-omics mapping positions antigenic myeloid-T cell crosstalk at the core of advanced renal cell carcinoma (aRCC) response to immune checkpoint blockade (ICB)
Presenter: Lisa Kinget
Session: Poster session 23
1908P - Utility of circulating tumor (ct)DNA testing for molecular residual disease (MRD) detection and treatment response monitoring in patients (pts) with renal cell carcinoma (RCC)
Presenter: Michael Smigelski
Session: Poster session 23
1909P - Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study
Presenter: Larissa Rainho
Session: Poster session 23
1910P - Evaluation of a genome-wide methylome enrichment platform for circulating tumor DNA quantification and prognostic performance in renal cell carcinoma (RCC)
Presenter: Brian Rini
Session: Poster session 23
1911P - Effect of VHL mutations on efficacy of immune checkpoint inhibitors in renal cell carcinoma
Presenter: Guojie Yu
Session: Poster session 23